Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | RAB9A | P51151 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | PIK3CG | P48736 | 11/20 | 0.48 |
| ▸ | ABL1 | P00519 | 1/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 9/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.41 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL172085 | 0.87 | ABL1 (0.49) | MEN1RAB9AKMT2ANPC1PIK3CG | |
| SCHEMBL172061 | 0.83 | MAPT (0.45) | MEN1RAB9AKMT2ANPC1ABL1 | |
| SCHEMBL171905 | 0.78 | PIK3CA (0.52) | PIK3CGPIK3CA | |
| SCHEMBL3782341 | 0.76 | PIK3CG (0.56) | RAB9ANPC1PIK3CGABL1PIK3CA | |
| SCHEMBL798733 | 0.76 | PIK3CG (0.61) | MEN1RAB9AKMT2ANPC1PIK3CG | |
| SCHEMBL13189215 | 0.75 | KMT2A (0.53) | MEN1RAB9AKMT2ANPC1PIK3CG | |
| SCHEMBL798739 | 0.75 | KDM4E (0.41) | MEN1RAB9AKMT2ANPC1MAPT | |
| SCHEMBL799218 | 0.74 | RAB9A (0.56) | MEN1RAB9AKMT2ANPC1ABL1 | |
| SCHEMBL798968 | 0.73 | PIK3CG (0.60) | PIK3CGPIK3CA | |
| SCHEMBL798966 | 0.73 | MEN1 (0.52) | MEN1RAB9AKMT2ANPC1PIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120071475-A1 | UREA DERIVATIVES HAVING PI3K-INHIBITING ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2012-03-22 | — | — | US | disclosed |
| US-20120071475-A1 | UREA DERIVATIVES HAVING PI3K-INHIBITING ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071475-A1 | UREA DERIVATIVES HAVING PI3K-INHIBITING ACTIVITY | MTOR, STAT3, SLC14A1 | MEN1 2694/4885RAB9A 1096/4885KMT2A 2921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.